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In immunocompromized patients, including hematopoietic stem cell transplant (HSCT) recipients, life-threatening toxoplas-
mosis may result from reactivation of previous infection. We report a case of severe disseminated toxoplasmosis that developed
early after allogeneic HSCT for T-cell lymphoblastic leukemia/lymphoma in a 15-year-old Toxoplasma gondii-seropositive boy
with Nijmegen breakage syndrome, a rare genetic DNA repair disorder associated with immunodeficiency. The donor was the
patient’s HLA-identical brother. Prophylaxis with cotrimoxazole was discontinued a day before the HSCT procedure. Signs of
lung infection appeared as early as day 14 post-HSCT. The presence of tachyzoite-like structures on Giemsa-stained bronchoal-
veolar lavage (BAL) fluid smears suggested toxoplasmosis. Real-time PCR targeted at the T. gondii AF146527 gene revealed ex-
tremely high parasite burdens in both blood and BAL fluid. Although immediate introduction of specific treatment resulted in a
marked reduction of the parasite load and transient clinical improvement, the patient deteriorated and died of multiple organ
failure on day 39 post-HSCT. Direct genotyping of T. gondii DNA from blood and BAL fluid with the PCR-restriction fragment
length polymorphism method revealed type II alleles with SAG1, SAG2, and GRA6 markers but alleles of both type I and type II
with GRA7. Additional analysis with 15 microsatellite markers showed that the T. gondii DNA was atypical and genetically di-
vergent from that of the clonal type I, II, and III strains. This is the first report of increased clinical severity of toxoplasmosis as-
sociated with an atypical strain in the setting of immunosuppression, which emphasizes the need to diagnose and monitor toxo-
plasmosis by quantitative molecular methods in cases of reactivation risk.
Toxoplasma gondii is a protozoan parasite distributed world-wide and infecting one-third of the global population. Infec-
tion is acquired by ingestion of parasites via consumption of un-
dercooked meat containing tissue cysts or of water, fruits, or
vegetables contaminated with oocysts. In immunocompetent in-
dividuals, primary infection results in the formation of tissue cysts
and in serological evidence of infection. However, in immuno-
compromized patients, such as hematopoietic stem cell transplant
(HSCT) recipients, toxoplasmosis is often a life-threatening op-
portunistic infection arising either from transmission of the par-
asites via a graft from a seropositive donor to a seronegative recip-
ient or, far more frequently, from reactivation of a preexisting
latent infection in a seropositive recipient, regardless of the do-
nor’s serological status (1). After allogeneic HSCT, studies have
shown an incidence of invasive toxoplasmosis among seropositive
recipients of 4% to 6%, with an estimated mortality rate of 60% to
90% (2, 3).
Nijmegen breakage syndrome (NBS) is a rare, autosome-reces-
sive DNA repair disorder characterized by microcephaly with nor-
mal intelligence, facial dysmorphia (bird-like facial features), pri-
mary immunodeficiency, and a predisposition to lymphoid
malignancies at a young age (4, 5). Treatment of NBS-related ma-
lignancies is challenging due to the chromosomal instability and
immunodeficiency which make the patients more susceptible to
the toxic effects of standard chemotherapy and radiation. Al-
though lymphoid malignancies occurring in NBS patients can be
successfully brought into remission using standard chemotherapy
regimens with minor dose modifications (6, 7), a high rate of
treatment failure and relapse has been observed (8). An alternative
treatment option for malignancies in NBS is HSCT from HLA-
identical donors, which has been shown not only to correct hu-
moral and cellular immunodeficiency but also to lower the sec-
ondary malignancy rate (9).
We here present a case of an early and fulminant post-HSCT
reactivation of toxoplasmosis caused by an atypical T. gondii strain
in a young patient with NBS that contributed to a subsequent fatal
outcome within 40 days after transplantation. This case is the first
report of increased clinical severity of toxoplasmosis caused by an
atypical strain in the setting of immunosuppression. It also
stresses the value and necessity of the use of quantitative molecular
methods to monitor T. gondii reactivation in cases of reactivation
risk.
(The results of this study have been presented in part at the
11th European Multicolloquium of Parasitology [EMOP XI],
Cluj-Napoca, Romania, 25 to 29 July 2012.)
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A 15-year-old male patient with NBS was admitted at the Mother
and Child Health Care Institute of Serbia for planned HSCT from
a HLA-identical sibling. His past medical history revealed no re-
current infections during childhood.
The first hospitalization at the Institute was in October 2010,
when a diagnosis of T-cell lymphoblastic leukemia/lymphoma
(TLBL/ALL) was established. The patient received modified che-
motherapy leading to complete clinical and laboratory remission
of TLBL/ALL. At the time, microcephaly along with characteristic
facial features, including large ears, prominent midface, and re-
ceding mandible, raised suspicion of NBS. Diagnosis of NBS was
confirmed by a mutation analysis of the NBN(NBS1) gene which
revealed a homozygous state for a typical 5-bp deletion
(g.657del.5). Immunodeficiency was characterized by low serum
IgA (0.57 g/liter) and IgM (0.36 g/liter) concentrations, while IgG
was within the normal range for his age.
HSCT was performed in November 2011. Before HSCT, he
received a standard reduced-intensity fludarabine-based condi-
tioning regimen according to the European Blood and Marrow
Transplantation-Inborn Errors Working Party guidelines, with-
out irradiation. Acute graft-versus-host disease (GVHD) prophy-
laxis consisted of cyclosporine. Pretransplantation serological
screening for toxoplasmosis revealed a donor-recipient mismatch,
i.e., the donor was seronegative, while the recipient had serological
(enzyme-linked immunosorbent assay [ELISA]) (Enzygnost
Toxo IgG and Enzygnost Toxo IgM tests; Siemens Healthcare Di-
agnostics, Marburg, Germany) evidence of past infection (Table
1). Trimethoprim-sulfamethoxazole (TMP-SMX) administered
for prophylaxis of Pneumocystis jirovecii pneumonia was consid-
ered to cover toxoplasmosis as well but was discontinued a day
before HSCT, following the guidelines to avoid an early graft fail-
ure (10).
The HSCT procedure performed using his HLA-identical male
sibling was uneventful. On day 6 after HSCT, the patient devel-
oped mild skin and gut GVHD stage I, for which prednisone at a
dose of 1 mg/kg of body weight/day was given. On day 14 post-
HSCT, intensive chest pain appeared. A chest X-ray showed left-
sided pleural effusion. Bronchoscopy was performed on day 20,
and a bronchoalveolar lavage (BAL) fluid sample was obtained.
The initial workup ruled out common infection (all bacterial
and fungal cultures were negative). However, visualization of
tachyzoite-like structures on Giemsa-stained BAL fluid smears
suggested toxoplasmosis (Fig. 1). The patient was immediately



















index Blood BAL fluid
21 578 ND ND ND neg. ND neg. ND ND
21 ND 1:640 144 0.566 ND 3 0.09 15,000 100,000
30 ND 1:1,280 287 ND ND 0 0.10 200 ND
a Positivity thresholds for IgG, 5 IU/ml for ELISA (Enzygnost Toxo IgG, Siemens), 1:40 for HSDA, and 8 IU/ml for TXG Vidas (bioMérieux). For IgM, ELISA (Enzygnost
Toxo IgM, Siemens) absorbance values, 0.3; TXM Vidas (bioMérieux) index, 0.65; ISAgA (bioMérieux) index, 9 to 12. For TXGA Vidas (bioMérieux), low index (I), I  0.200;
intermediate index, 0.200  I  0.300; high index, I  0.300. ND, not done; neg., negative.
b Number of parasites/ml of sample quantified by real-time PCR.
FIG 1 T. gondii tachyzoites on Giemsa-stained BAL fluid smears on post-HSCT day 20.
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started on intravenous TMP-SMX (high-dosage regimen of TMP
of 15 mg/kg/day) and clindamycin (CLI). On day 21 post-HSCT,
the patient’s blood and BAL fluid samples were referred to the
Serbian National Reference Laboratory for Toxoplasmosis (NRL-
Toxo) for confirmation. Serological findings merely confirmed
the seropositive status of the patient, but using molecular meth-
ods, T. gondii dissemination was diagnosed, with extremely high
parasite burdens in both blood and BAL fluid (Table 1). By that
time, however, the patient had developed acute respiratory dis-
tress syndrome (ARDS) requiring mechanical ventilation. His
condition was further exacerbated by acute renal failure necessi-
tating continuous veno-venous hemodiafiltration (CVVHDF).
TMP-SMX and CLI treatment led to gradual clinical and radio-
logical improvement of both respiratory and renal functions, i.e.,
to reduced pleural effusion (although mechanical ventilation was
still required due to respiratory insufficiency), and to establish-
ment of diuresis at 1 ml/kg/h followed by reduction of urea and
creatinine levels, which allowed the discontinuation of CVVHDF.
Subsequent serological testing performed on day 30 post-
HSCT showed a 2-fold rise in specific IgG antibody while specific
IgM remained undetectable, whereas control real-time PCR (RT-
PCR) at this time point reflected a dramatic decrease in the para-
site burden in the blood (Table 1).
However, after a transient improvement (day 25 to day 32
post-HSCT), fever and further deterioration of the respiratory
function ensued, along with an increase in inflammatory markers.
Multidrug-resistant strains of Acinetobacter baumannii, Klebsiella
pneumoniae, and Achromobacter xylosoxidans were isolated from
the endotracheal aspirate on day 35 and Acinetobacter baumannii
was isolated from blood culture on day 37 post-HSCT. Despite
immediate introduction of appropriate antimicrobial treatment,
the patient continued to deteriorate and died of sepsis compli-
cated by multiple organ failure on day 39 post-HSCT.
MATERIALS AND METHODS
Clinical samples. Peripheral blood and BAL fluid were sampled for serol-
ogy (blood), microscopic detection of the parasite in Giemsa-stained
preparations (BAL fluid), and detection of parasite DNA (blood and BAL
fluid). Whole blood was centrifuged, and the serum and buffy coat were
used for serological testing and DNA extraction, respectively. BAL fluid
was centrifuged and the pellet used in part for staining with Giemsa and in
part for DNA extraction. Between analyses, all samples were stored at
20°C.
Serology. Serological tests included the high-sensitivity direct agglu-
tination (HSDA) test (11) and commercial assays, including TXG- and
TXM-Vidas (bioMérieux, Marcy l’Etoile, France) for specific IgG and IgM
antibodies, respectively, and an immunosorbent agglutination assay
(ISAgA) (bioMérieux) for specific IgM antibodies. Specific IgG avidity
was measured by TXGA-Vidas (bioMérieux). Commercial assays were
carried out according to the manufacturer’s recommendations, and the
results expressed in IU/ml (TXG-Vidas) or as indices (all others). HSDA
results were expressed as the highest serum dilution at which the reaction
was positive (titer).
Molecular detection of T. gondii DNA. Complete DNA from blood
and BAL fluid samples was extracted with a QIAmp DNA minikit
(Qiagen, Hilden, Germany) according to the manufacturer’s instructions,
resuspended in 150 l of nuclease-free water, and stored at 20°C. The T.
gondii AF146527 gene (529-bp repetitive element), occurring up to 200 to
300 times in the T. gondii genome, was detected with a TaqMan probe (10
pmol/l) (6-carboxyfluorescein [FAM]–ACG CTT TCC TCG TGG TGA
TGG CG– 6-carboxytetramethylrhodamine [TAMRA]) (12, 13). PCR was
performed in a final volume of a 20-l mixture containing 10 l Maxima
Probe/ROX quantitative PCR (qPCR) Master Mix (Fermentas [Thermo
Fisher Scientific], Waltham, MA) (2), 0.25 mM (each) primer, 0.10 mM
TaqMan probe (Invitrogen, Life Technologies, Carlsbad, CA), 0.015 U/l
of uracil N-glycosylase (UNG), 25 mM MgCl2, and nuclease-free water
plus 3 l of extracted DNA. Amplification was performed over 40 cycles in
an Eppendorf RT-PCR device (Eppendorf, Hamburg, Germany), using
the following cycling conditions: 2 min at 50°C for UDG pretreatment and
10 min at 94°C for initial denaturation followed by 40 cycles of 15 s at 95°C
for denaturation and 60 s at 60°C for annealing/extension.
Genotyping analysis. Genotyping of T. gondii DNA in the blood and
BAL fluid samples was initially performed at the NRLToxo by the PCR-
restricted fragment length polymorphism (RFLP) method based on four
markers, including SAG1, SAG2, GRA6, and GRA7. For each marker, the
PCR mixture consisted of 12.5 l PCR Master Mix (Fermentas) (2), 1 l
10 M (each) forward and reverse primer, 7.5 l nuclease-free water, and
3 l DNA extracted from the sample in a 25-l reaction volume. Positive
controls consisted of T. gondii type I (RH), type II (Me49), and type III
(NED) strains, while nuclease-free water was used as a negative control.
PCR products were digested with appropriate restriction enzymes for dif-
ferent markers. The PCR mixture for digestion consisted of 12 l of nu-
clease-free water, 2.5 l of buffer, and 0.5 l of the appropriate restriction
enzyme. Restriction products were visualized by electrophoresis using a
3% agarose gel stained with ethidium bromide. Estimation of fragment
size was based on comparison to a 50-bp DNA ladder (Fermentas).
T. gondii DNA in the blood sample was further genotyped at the
French National Reference Center for toxoplasmosis with 15 microsatel-
lite markers distributed over 10 of 14 chromosomes, as described previ-
ously (14). Briefly, for each primer pair, the forward primer was 5= end
labeled with fluorescein to allow sizing of PCR products electrophoresed
in an automatic sequencer. PCR was carried out in a 25-l reaction mix-
ture consisting of 12.5 l of 2 Qiagen Multiplex PCR Master Mix (Qia-
gen, Courtaboeuf, France), 5 pmol of each primer, and 1 l of DNA.
Cycling conditions were 15 min at 95°C; 30 s at 94°C, 3 min at 61°C, and
30 s at 72°C (35 cycles); and 30 min at 60°C. One l of the PCR product—
diluted 1:20 in deionized formamide—was mixed with 0.5 l of a dye-
labeled size standard (ROX 500; Applied Biosystems, Courtabœuf,
France) and 23.5 l of deionized formamide (Applied Biosystems). This
mixture was denatured at 95°C for 5 min and then electrophoresed using
an automatic sequencer (ABI Prism 3130xl; Applied Biosystems). The
sizes of the alleles in bp were estimated using GeneMapper analysis soft-
ware (version 4.0, Applied Biosystems).
RESULTS
Microscopic examination of Giemsa-stained BAL fluid smears
and visualization of tachyzoites on day 20 post-HSCT indicated
further testing in the NRLToxo. Serological analysis showed
high-avidity specific IgG antibodies without specific IgM (trace
amounts, however, were detected by the highly sensitive ISAgA
assay) (Table 1). RT-PCR revealed parasite DNA, and the parasite
burden was estimated, according to a standard curve, at nearly
15,000 parasites/ml in the blood and at a staggering 100,000 par-
asites/ml in the BAL fluid.
Control serology on day 30 post-HSCT showed a 2-fold rise in
specific IgG antibodies (in both the commercial and HSDA tests)
without the appearance of specific IgM. A favorable response to
combination TMP-SMX and CLI therapy was reflected in transi-
tory clinical improvement, while RT-PCR revealed a dramatically
reduced parasite load of approximately 200 parasites/ml.
T. gondii DNA characterization. Direct genotyping of T. gon-
dii DNA from both the blood and BAL fluid samples with PCR-
RFLP revealed that the parasite had type II alleles with the SAG1,
SAG2, and GRA6 markers but alleles of both type I and type II with
the GRA7 marker. This result triggered additional genotyping
analysis with microsatellite markers which showed that the T. gon-
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dii DNA from the blood sample— designated TgH106019 —was
atypical and genetically divergent from the clonal type I, II, and III
strains commonly found in western Europe or North America
(Table 2). Furthermore, the allelic combination of this genotype
with microsatellite markers was very uncommon, as it was also
divergent from the pattern seen with genotypes of African, South
American, and Asian strains available at the Toxoplasma Biologi-
cal Resource Center collection in Limoges, France.
DISCUSSION
The presented case of fulminant clinical reactivation of an atypical
T. gondii strain in a HSCT recipient with underlying NBS, a rare
DNA repair disorder and immunodeficiency, is apparently the
first such case ever described. Reactivation of T. gondii developed
within days after HSCT and significantly contributed to the fatal
outcome.
In seropositive allogeneic HSCT recipients, the hazard of T.
gondii reactivation is generally high. The donor’s seronegative sta-
tus seems to contribute to this risk, as approximately 80% of all
reported events of toxoplasmosis are observed in cases of donor/
recipient serological mismatch (3, 15). Clinical symptoms of re-
activation are usually observed within 2 to 4 months post-HSCT
(1), with a median onset at 64 days (2) and with fewer than 10% of
cases occurring before day 30 post-HSCT (1). While toxoplasmic
encephalitis is the most frequent presentation, the lungs are the
most common site of extracerebral toxoplasmosis (16, 17). Pneu-
monitis, followed by ARDS and rapid dissemination resulting in
multiple organ failure, is not rare in HSCT recipients, a setting in
which it is usually manifested early, during the first month post-
HSCT, and is often fatal (10, 18).
Although serology remains the mainstay in the diagnosis of
toxoplasmosis, its value in immunosuppressed patients is limited
by the inability to mount an adequate humoral immune response.
Indeed, the concentration of specific IgG is, in most cases, includ-
ing the one presented here, at levels below the ones registered
pretransplantation (15). Hence, the definitive diagnosis of reacti-
vated toxoplasmosis in HSCT recipients is based on the isolation
of the parasite or on the detection of parasitic DNA in blood, body
fluids, or tissues. Although direct microscopy is generally ne-
glected due to its low sensitivity, it is the simplest and most rapid
means to diagnose disseminated toxoplasmosis (1, 15). In the pre-
sented case, toxoplasmosis was suggested by visualization of
tachyzoites on microscopic examination of Giemsa-stained BAL
fluid smears. However, only PCR-based methods, particularly the
quantitative ones, allow both timely introduction of specific treat-
ment and monitoring of the therapeutic response (3, 18, 19). In-
deed, in our patient, the extremely high initial parasite loads, as
revealed by RT-PCR in both blood and BAL fluid, significantly
decreased only after several days of specific treatment, indicating a
good therapeutic response.
The patient’s genetic immunodeficiency (both cellular and hu-
moral), aggravated by immunosuppressive therapy both pre- and
posttransplantation, likely triggered an early toxoplasmosis reac-
tivation (2, 15). Additional factors that may have contributed to
early and heavy T. gondii dissemination and rapid clinical deteri-
oration include the absence of posttransplantation prophylaxis in
an immunosuppressed seropositive HSCT recipient, who, more-
over, received a graft from a seronegative donor, and the atypical
genotype of the T. gondii strain involved.
For prophylaxis, there is no common ground with respect to
either the specific drugs used for the prevention of T. gondii dis-
semination or the time of initiation and duration of prophylaxis.
The most widely used prophylactic regimen is a combination of
TMP and SMX, while a positive PCR result from blood (indicating
reactivation) requires a switch to pyrimethamine-sulfadiazine
(PYR-SDZ) or PYR-CLI or raising the doses of TMP-SMX (3). In
the presented case, however, post-HSCT prophylaxis was with-
held to avoid jeopardizing engraftment (10) based on reports in-
dicating that 90% of the cases of reactivation occur later (be-
yond 30 days post-HSCT) (1). However, PCR-based preemptive
therapy may protect against death due to toxoplasmosis in ap-
proximately 80% of patients (3). Thus, a decision to withhold
post-HSCT prophylaxis should entail a weekly PCR follow-up,
and based on previous studies (3, 19) and this report, RT-PCR
(from blood) should be used for routine monitoring in all sero-
positive patients from day 1 post-HSCT.
The T. gondii population structure consists of three major
clonal lineages designated types I, II, and III which are, with an
emphasis on type II, predominant in Europe and North America
(20, 21), whereas the strains isolated in Africa and South America
are highly polymorphic and referred to as atypical (22). Limited
experience with T. gondii genotypes circulating in southeastern
Europe indicates the presence of only clonal types, with the pre-
dominance of type II (23, 24, 25). However, the infecting strain in
the reported patient was genetically divergent from strains com-
monly isolated in Europe. Epidemiological data indicated no ex-
planation as to its origin, since the patient was born and raised in
Montenegro (a southeastern Europe country neighboring Serbia)
TABLE 2 Genotyping results of T. gondii DNA with 15 microsatellite markers from a blood sample of the present case (TgH106019) and from 7
reference strains collected in North America, South America, Africa, Asia, and western Europe
Type Isolatea Origin Host
Microsatellite marker
TUB2 W35 TgM-A B18 B17 M33 IV.1 XI.1 M48 M102 N60 N82 AA N61 N83
Atypical TgH106019 Serbia Human 291 242 203 156 336 165 274 354 223 174 130 109 NAb 101 310
I CT1 United States Cow 291 248 209 160 342 169 274 358 209 168 145 119 265 87 306
II TgH32006 France Human 289 242 207 158 336 169 274 356 215 174 142 111 281 91 310
II TgA32132 France Sheep 289 242 207 158 336 169 274 356 221 174 138 111 277 91 312
III NED France Human 289 242 205 160 336 165 278 356 209 190 147 111 267 91 312
South American 1 TgH24001 Brazil Human 289 242 205 160 342 165 278 358 237 164 145 111 316 89 308
African 1 TgH32052 Benin Human 291 248 205 160 342 165 274 354 231 166 147 111 273 89 306
Chinese 1 TgCtPRC04 China Cat 293 242 211 160 336 169 274 354 215 172 145 123 281 93 308
a TgA32132 is also known as strain FR-OVI-ARI061; all reference strains, except TgCtPRC04, are available at the Toxoplasma Biological Resource Center, Limoges, France.
b NA, not amplified.
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and never traveled outside Europe and his dietary habits were
described as nonhazardous. So, the atypical genotype suggests ei-
ther that foodstuffs from areas with atypical strains had somehow
found their way to the local market or that there is a larger genetic
diversity of T. gondii in southeastern Europe, an option that needs
to be further explored.
Atypical T. gondii strains have been shown to correlate with in-
creased clinical severity of the infection in immunocompetent pa-
tients (26) and congenital toxoplasmosis (27), but this is the first
report of such an association in an immunocompromized patient
previously not evidenced in the setting of immunosuppression (22).
In contrast, Patrat-Delon et al. recently reported a favorable outcome
in a heart transplant patient with fulminant T. gondii reactivation
(although at much lower parasite loads than described here), in
which the infecting strain was a typical clonal (type II) one (19).
In conclusion, for HSCT to prove the beneficial treatment op-
tion in NBS patients with lymphoid malignancies that it promises
to be in terms of survival rate improvement, absence of relapses,
and correction of underlying immunodeficiency (9), centers per-
forming such a delicate procedure must be aware of T. gondii-
related risks. In cases of presumed reactivation risk such as in
seropositive HSCT patients, routine monitoring of toxoplasmosis
by PCR-based quantitative methods (at present, RT-PCR) should
be part of the standard follow-up protocol.
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